Roundup Settlement Amounts 2026: $7.25B Settlement Payout Range

Roundup settlement amounts are unusual among mass torts in that real, published per-claimant numbers exist — and equally unusual in that a Supreme Court ruling has just moved against claimants. This guide covers both, because either on its own gives a misleading picture of what a Roundup claim is worth in 2026.

Where Things Stand in 2026

Roundup litigation concerns claims that glyphosate, the active herbicide in Roundup, caused non-Hodgkin lymphoma, and that Monsanto — acquired by Bayer in 2018 — failed to warn users of the risk.

This is a mature litigation, not an emerging one. Bayer has already resolved roughly 100,000 claims at a cost of about $11 billion since 2020. What remains is roughly 61,000 active claims, split between the federal MDL, a large concentration in Missouri state court, and other state filings.

Two developments in 2026 dominate everything else: a proposed $7.25 billion class settlement that has not yet been finally approved, and a Supreme Court ruling that materially weakens the legal theory most of these claims rest on. They pull in opposite directions, and any honest assessment of claim value has to hold both.

Roundup Settlement Amounts Under the $7.25 Billion Class Settlement

Bayer announced the settlement on 17 February 2026. Unlike most mass tort resolutions, its structure has been described publicly in enough detail to give claimants real numbers.

• Scope: current and future non-Hodgkin lymphoma claims — a class settlement designed to close the litigation rather than resolve one tranche of it.
• Projected individual awards: $6,000 to $165,000, varying by exposure type, age at diagnosis, and whether the lymphoma is aggressive or indolent.
• Payment period: approximately 21 years.
• Expedited option: claimants aged 78 or older, and those with residential rather than occupational exposure, may qualify for “quick-pay” awards — faster, but at lower amounts.
• Opt-out deadline: 4 June 2026, for claimants choosing to pursue their claims individually instead.

Two features deserve attention. The range top of $165,000 is far below the headline verdicts discussed further down, which is the normal relationship between settlement values and outlier jury awards — settlements price the average case and the risk of losing, not the best case. And a 21-year payment period means the nominal total and the present value of an individual award are not the same thing.

The settlement is not final. Preliminary approval came in March 2026, but the final approval hearing was rescheduled to 14 September 2026, and as of late August 2026 no final approval had been granted. Until it is, the payout structure above is a proposal.

The Supreme Court Ruling That Changed the Leverage

On 25 June 2026 the U.S. Supreme Court decided Durnell v. Monsanto by a 7–2 margin, siding with Bayer on federal preemption. In substance, the Court held that where the EPA has approved a pesticide label, federal law can preempt state-law claims alleging the manufacturer should have warned differently.

This matters to claim value directly. Failure-to-warn is the central theory in most Roundup cases, and preemption is a defence that can defeat a claim regardless of the scientific evidence about glyphosate. A ruling that strengthens that defence reduces the settlement pressure on Bayer and increases the risk that individual claims fail on a legal question rather than a factual one.

Anyone weighing whether to participate in the settlement or opt out should understand that the litigation landscape after 25 June 2026 is materially less favourable to claimants than it was before. That is not a reason to abandon a claim — the ruling’s reach across different states and claim types will be litigated for some time — but it is a reason to be sceptical of any source still quoting pre-ruling expectations.

The Verdict Record

Roundup has produced some of the largest product-liability verdicts in US history. It has also produced a substantial number of defence verdicts, and the two facts belong together.

Date	Case	Court	Award
January 2024	McKivison	Pennsylvania	$2.25 billion — largest single Roundup verdict
October 2024	Philadelphia trial	Pennsylvania	$78 million
March 2025	Barnes	Georgia	$2.065 billion

Across 18 trials, plaintiffs prevailed in 10 — and three of those exceeded $1 billion. That means defendants won 8. It also means a claimant reading a billion-dollar headline is looking at the extreme tail of a distribution in which roughly 44% of tried cases produced nothing at all.

Large punitive awards in this litigation have also been reduced substantially on post-trial motions and appeal, which is the norm rather than the exception. The gap between a $2.25 billion verdict and a $6,000–$165,000 settlement range is not evidence that the settlement is unfair; it reflects the difference between the best possible outcome in one case and the negotiated average across tens of thousands.

Factors That Affect Your Settlement Value

• Diagnosis — non-Hodgkin lymphoma is the covered condition, and whether it is aggressive or indolent affects placement in the range.
• Exposure type — occupational and agricultural exposure generally carries more weight than residential or garden use, which is directed toward the lower quick-pay band.
• Age at diagnosis — younger claimants generally have larger economic loss; claimants aged 78 and over are routed toward expedited lower awards.
• Duration and intensity of use — years of application, frequency, and whether protective equipment was used.
• Documentation — purchase records, employment history, pathology and staging.
• Venue — for those who opt out, the state and court in which a claim is filed matters more than usual after the preemption ruling.

Who Qualifies

Claims generally require a non-Hodgkin lymphoma diagnosis together with a documented history of Roundup or glyphosate exposure, brought within the applicable limitation period.

The class settlement is designed to cover both existing claimants and people diagnosed in future, which is unusual and is part of why it required court approval rather than simple agreement. Whether an individual is inside or outside the class, and whether opting out serves their interests, is a question for a lawyer — and one that the June preemption ruling has made harder rather than easier.

Timeline and Deadlines

The critical date is the final approval hearing, rescheduled to 14 September 2026. If approval is granted, the claims administration process begins and payments follow the tiered structure over roughly two decades. If it is not, the litigation continues in its current posture — with a preemption ruling that now favours the defence.

Until approval is granted, Roundup settlement amounts remain proposed rather than payable. The opt-out deadline of 4 June 2026 has passed. Claimants who did not opt out are within the proposed class if it is approved. Anyone uncertain about their status should confirm it rather than assume.

Use the Roundup Settlement Calculator

Our free Roundup Settlement Calculator helps organise the exposure history, diagnosis and documentation that determine placement within the settlement range. It produces an educational estimate, not an offer.

How a Roundup Settlement Is Actually Paid

The $6,000 to $165,000 band published with the class settlement is a gross range, and it is structured to be paid over roughly 21 years rather than as a single cheque. Both facts change what the numbers mean in practice, and neither is usually mentioned alongside them.

From a gross allocation come the contingency fee and case expenses set out in the retainer agreement, then repayment of medical liens. Non-Hodgkin lymphoma treatment is expensive — chemotherapy, radiation and in some cases transplant — so whoever paid for it, whether a private insurer, Medicare or Medicaid, has a right to be reimbursed from the settlement. Those amounts can often be reduced through formal lien resolution, but they are rarely trivial.

The staged payment schedule matters for a second reason: it is designed to cover future claimants as well as current ones. A settlement that must remain solvent for two decades is priced conservatively by design, which is part of why the per-claimant band sits so far below the headline verdicts.

None of this is payable yet. Until the final approval hearing on 14 September 2026, the structure is proposed. If approval is refused, claims return to litigation in a landscape now shaped by the Supreme Court’s preemption ruling.

What to Gather Before Speaking to a Lawyer

Roundup claims turn on two things: a confirmed non-Hodgkin lymphoma diagnosis, and documented exposure substantial enough to connect the two. The medical half is usually straightforward, because pathology reports exist. The exposure half is where claims are won and lost.

Useful exposure evidence includes purchase records, employment records for agricultural, landscaping, groundskeeping or municipal work, pesticide applicator licences and training certificates, and statements from co-workers, family members or neighbours who can confirm regular use over a period of years. Frequency and duration both matter, and so does the setting: occupational exposure generally carries more weight than occasional residential use.

On the medical side, the pathology report identifying the lymphoma subtype is the single most important document, because the tiered structure distinguishes between aggressive and indolent disease. Treatment records, remission and relapse history, and documentation of lost earnings and future care complete the picture.

Claimants should also expect the defence to raise alternative causes — immunosuppression, other chemical exposures, family history of haematological cancer. These do not end a claim, and disclosing them early is better than having them surface later.

Common Misconceptions About Roundup Settlement Amounts

“Juries awarded billions, so my claim is worth millions.”

Across 18 Roundup trials, plaintiffs prevailed in 10 and defendants in 8 — roughly 44% of tried cases produced nothing at all. Of the wins, three exceeded $1 billion, and those figures were driven by punitive damages that were substantially reduced on post-trial motions and appeal. A billion-dollar headline is the extreme tail of a distribution, not its centre.

“The $7.25 billion settlement means payouts are coming.”

It is a proposed class settlement. It received preliminary approval in March 2026, but the final approval hearing was rescheduled to 14 September 2026 and, as of late August 2026, approval had not been granted. Preliminary approval is a finding that terms are worth putting to the class, not a decision that they are fair.

“The Supreme Court ruling does not affect my case.”

It probably does. In Durnell v. Monsanto, decided 25 June 2026, the Court held 7–2 for Bayer on federal preemption — a ruling that goes to the heart of the state-law failure-to-warn theory most Roundup claims rest on. It does not extinguish claims, but it strengthens Bayer’s hand in any case that continues to be litigated, and that is part of why the proposed settlement band looks the way it does.

“It is too late to do anything because the opt-out deadline has passed.”

The 4 June 2026 opt-out deadline has passed, which means claimants who did not opt out are within the proposed class if it is approved. That is a reason to confirm your status rather than assume it. Anyone uncertain whether they are in the class, and what that means for a claim already filed, should establish it now rather than after the approval hearing.

“Bayer already paid $11 billion, so there is plenty left.”

The roughly $11 billion Bayer has paid since 2020 resolved about 100,000 claims — it is money already spent, not a fund waiting to be distributed. Around 61,000 claims remain active, and the proposed $7.25 billion is what has been offered to resolve current and future non-Hodgkin lymphoma claims going forward. Reading the historical spend as available money is the most common way people overestimate Roundup settlement amounts.

“State court claims are unaffected by the class settlement.”

Roughly 30,000 Roundup claims sit in Cole County, Missouri, alongside about 3,932 pending in the federal MDL before Judge Vince Chhabria. A class settlement of this kind is designed to resolve claims across both tracks, which is why the opt-out mechanism existed at all. Where a claim was filed affects timing and procedure; it does not put the claim outside the settlement automatically.

Frequently Asked Questions

How much is the average Roundup settlement?

There is no published average. Roundup settlement amounts under the proposed $7.25 billion class settlement are projected at $6,000 to $165,000 per claimant, depending on exposure type, age at diagnosis and whether the lymphoma is aggressive or indolent. That structure is not final — the approval hearing was rescheduled to 14 September 2026.

Why is the settlement range so much lower than the billion-dollar verdicts?

Because they measure different things. Verdicts are the outcome of individual trials, often include punitive damages, and are frequently reduced on appeal. Across 18 Roundup trials, plaintiffs won 10 and defendants won 8. A settlement prices the average claim and the risk of losing, across tens of thousands of people.

What did the Supreme Court decide in June 2026?

In Durnell v. Monsanto, decided 25 June 2026 by a 7–2 vote, the Court sided with Bayer on federal preemption — holding that EPA approval of a pesticide label can preempt state-law failure-to-warn claims. It is a significant setback for claimants pursuing individual claims outside the settlement.

Has Bayer already paid Roundup claims?

Yes. Bayer has paid approximately $11 billion resolving around 100,000 lawsuits since 2020. Roughly 61,000 claims remain active.

Can I still file a Roundup claim?

Claims are still being filed, but the position is more complicated than it was. The opt-out deadline has passed, the class settlement awaits final approval, and the preemption ruling affects claims pursued individually. Limitation periods vary by state and run from diagnosis or discovery.

Sources

Settlement terms, court identifiers and verdicts on this page are drawn from the defendant’s own disclosures and public court records. Where a figure is a projection under a proposed settlement rather than a paid amount, it is labelled as such.

• Bayer — Managing the Roundup Litigation — the defendant’s own record of the settlement announcement, the rescheduled 14 September 2026 approval hearing, and the Supreme Court ruling.
• Judicial Panel on Multidistrict Litigation — Pending MDL Dockets — source for MDL 2741 pending action counts.
• Supreme Court of the United States — opinions and docket for Durnell v. Monsanto.
• U.S. EPA — Glyphosate — federal regulatory position on the herbicide at the centre of the preemption question.
• National Cancer Institute — Adult Non-Hodgkin Lymphoma — medical background on the diagnosis at issue.

Related Roundup Resources

• Monsanto Roundup Lawsuit — eligibility, injuries and how claims are filed.
• Roundup Settlement Calculator — organise your exposure history and diagnosis.
• Toxic Exposure Lawsuits — other chemical exposure claims.
• Settlement Amounts — payout guides across all case types.

About the Author

Mason Arnao is a legal content strategist and mass tort researcher at TortAdvisor.com. He covers emerging litigation, settlement trends, and consumer legal rights across pharmaceutical, product liability, and personal injury law.